/
Other
ART
89
Pipeline Programs↗
79
Active Trials↗
140
Companies Involved↗
ART is a moderately active landscape with 89 programs across 140 companies. The most active players are Eli Lilly, Terran Biosciences Australia Pty Ltd, Moderna. 13 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical21
Phase 139
Phase 216
Phase 313
Approved
No programs
Analysis
Modality Breakdown
88%
Small molecule
73 of 83 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 83 classified programs, each share of the total. Modality classified for 100% of 89 pipeline programs.
Analysis
Trial Status
1,004
clinical trials
Completed785 · 78%
Terminated71 · 7%
Unknown status42 · 4%
Recruiting35 · 3%
Not yet recruiting26 · 3%
Withdrawn23 · 2%
Other22 · 2%
Clinical Trials
Trial Activity
1004 trials
Page 1 of 67
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)